BioAtla Inc Share Price Today: Live Updates & Key Insights

BioAtla Inc share price today is $0.16, up 7.87%. The stock opened at $0.1619 against the previous close of $0.1563, with an intraday high of $0.1673 and low of $0.1579.

BioAtla Inc Share Price Chart

BioAtla Inc

us-stock
To Invest in {{usstockname}}
us-stock

BioAtla Inc Share Price Performance

$0.16 0.0787(7.87%) BCAB at 23 Mar 2026 12:09 PM Biotechnology
Lowest Today 0.1579
Highest Today 0.1673
Today’s Open 0.1619
Prev. Close 0.1563
52 Week High 1.43
52 Week Low 0.13
Day’s Range: Low 0.1579 High 0.1673
52-Week Range: Low 0.13 High 1.43
1 day return -
1 Week return -9.6
1 month return -12.25
3 month return -79.67
6 month return -73.4
1 year return -56.46
3 year return -92.99
5 year return -99.75
10 year return -

BioAtla Inc Institutional Holdings

Vanguard Group Inc 2.62

TANG CAPITAL MANAGEMENT LLC 1.85

Vanguard Total Stock Mkt Idx Inv 1.60

Acadian Asset Management LLC 1.25

Marshall Wace Asset Management Ltd 1.20

Millennium Management LLC 1.03

SQUAD Aguja Opportunities I 1.01

Renaissance Technologies Corp 0.95

Deutsche Bank AG 0.71

Geode Capital Management, LLC 0.67

BlackRock Inc 0.65

Vanguard Institutional Extnd Mkt Idx Tr 0.62

Jane Street Group LLC 0.47

Fidelity Extended Market Index 0.35

ADAR1 Capital Management LLC 0.25

State Street Corp 0.20

Xtrackers MSCI World Swap ETF 1C 0.20

Abante Quant Value FI 0.20

Northern Trust Corp 0.14

Blackrock Extended Mkt Fund CF 0.13

UBS Group AG 0.12

Extended Equity Market Fund K 0.11

Susquehanna International Group, LLP 0.11

Two Sigma Investments LLC 0.11

Fidelity Total Market Index 0.11

Fidelity Series Total Market Index 0.10

NT Ext Equity Mkt Idx Fd - L 0.09

Sheets Smith Investment Management 0.09

HRT FINANCIAL LLC 0.07

Mccormack Advisors International 0.07

Spartan Extended Market Index Pool F 0.06

Northern Trust Extended Eq Market Idx 0.06

Vanguard Instl Ttl Stck Mkt Idx Tr 0.06

SIMPLEX TRADING, LLC 0.05

Spartan Total Market Index Pool G 0.05

NT Ext Equity Mkt Idx Fd - NL 0.04

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.04

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Telescope Biotech Fund A FIL 0.02

Vanguard U.S. Eq Idx £ Acc 0.02

BioAtla Inc Market Status

Strong Buy: 2

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

BioAtla Inc Fundamentals

Market Cap 12.52 M

PB Ratio 2.681

PE Ratio 0.0

Enterprise Value 10.00 M

Total Assets 52.42 M

Volume 947890

BioAtla Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:250000 0.3M, FY20:429000 0.4M, FY19:5200000 5.2M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:250000 0.3M, FY20:429000 0.4M, FY19:5200000 5.2M

Annual Net worth FY23:-124080000 -124.1M, FY22:-105283000 -105.3M, FY21:-95406000 -95.4M, FY20:-37241000 -37.2M, FY19:-31402000 -31.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:11000000 11.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-56000 -0.1M, Q2/2025:-567000 -0.6M, Q1/2025:-183000 -0.2M, Q3/2024:11000000 11.0M, Q2/2024:-229000 -0.2M

Quarterly Net worth Q3/2025:-15778000 -15.8M, Q2/2025:-18711000 -18.7M, Q1/2025:-15334000 -15.3M, Q3/2024:-10586000 -10.6M, Q2/2024:-21072000 -21.1M

About BioAtla Inc & investment objective

Company Information BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 61

Industry Biotechnology

CEO Dr. Jay M. Short Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

BioAtla Inc FAQs

What is the share price of BioAtla Inc today?

The current share price of BioAtla Inc is $0.16.

Can I buy BioAtla Inc shares in India?

Yes, Indian investors can buy BioAtla Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy BioAtla Inc shares in India?

You can easily invest in BioAtla Inc shares from India by:

Can I buy fractional shares of BioAtla Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of BioAtla Inc?

BioAtla Inc has a market cap of $12.52 M.

In which sector does BioAtla Inc belong?

BioAtla Inc operates in the Biotechnology sector.

What documents are required to invest in BioAtla Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of BioAtla Inc?

The PE ratio of BioAtla Inc is N/A and the PB ratio is 2.68.